A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with usual maintenance therapy in subjects with Asthma

Trial Profile

A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with usual maintenance therapy in subjects with Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Vilanterol/fluticasone furoate (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Sep 2017 According to a GlaxoSmithKline media relaes, results presented at the European Respiratory Society (ERS) International Congress
    • 11 Sep 2017 Results published in a GlaxoSmithKline Media Release.
    • 11 Sep 2017 According to a GlaxoSmithKline media relaes, Ashley Woodcock from University of Manchester is the lead investigator.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top